CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27

Sumant Kulkarni, an analyst from Canaccord Genuity, reiterated the Buy rating on CervoMed. The associated price target remains the same with $27.00.

Sumant Kulkarni has given his Buy rating due to a combination of factors that balance clinical potential with current valuation. He highlights that CervoMed has aligned with the FDA on a Phase 3 design for neflamapimod in dementia with Lewy bodies, selected a final dosing regimen and formulation, and produced supportive MRI data that reinforce the drug’s therapeutic rationale in this underserved indication.

He also notes several upcoming catalysts, including Phase 2a readouts in stroke recovery and primary progressive aphasia, which could further validate the broader platform. While he emphasizes that successful execution still hinges on securing additional funding to run the Phase 3 DLB trial, he believes the stock remains materially undervalued versus the sizable unmet need and models meaningful long-term sales with a 33% probability of approval, supporting an unchanged $27 price target and a Buy rating.

In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $9.00 price target.